Prion biology in transfusion medicine: implications for lab testing

Area of Science:

• Neurology
• Infectious Diseases
• Biochemistry

Background:

• Transmissible spongiform encephalopathies (TSEs), including variant Creutzfeldt-Jakob disease (vCJD), have resurfaced with renewed governmental interest.
• The link between vCJD and beef consumption, alongside concerns about human-to-human transmission, has heightened public and scientific awareness.
• The long latency period of prion diseases and potential misdiagnosis in conditions like Alzheimer's disease necessitate urgent diagnostic and preventative measures.

Purpose of the Study:

• To highlight the challenges in developing reliable antemortem tests for prion diseases due to the lack of specificity for the pathogenic prion protein.
• To discuss the implications of TSEs on public health, particularly concerning blood transfusion safety and donor screening.
• To emphasize the need for legislative action and advancements in diagnostic and preventative strategies for prion diseases.

Main Methods:

• Review of existing literature and governmental investigations into TSEs.
• Analysis of diagnostic challenges, particularly the difficulty in developing specific antibody-based assays for prion proteins.
• Examination of epidemiological trends, including the incidence of BSE, vCJD, and CWD, and their public health impact.

Main Results:

• Currently, no reliable antemortem test exists for screening infected animals or humans for TSEs.
• The incidence of Bovine Spongiform Encephalopathy (BSE) is declining in the UK due to implemented control measures.
• Emerging evidence suggests a significant percentage of Alzheimer's patients may have been misdiagnosed, actually suffering from prion disease.

Conclusions:

• The growing incidence of TSEs, coupled with diagnostic limitations and transfusion transmission risks, mandates adherence to the precautionary principle.
• Legislative support for blood donor exclusionary criteria, antemortem test development, and pathogen removal from donated blood is essential.
• Advancements in prion disease testing and filtration technologies are anticipated to improve clinical diagnostics and transfusion safety in the near future.